Treatment-emergent adverse events in greater than or equal to 20% of patients
| TEAE, n (%) . | Primary analysis . | |||
|---|---|---|---|---|
| Overall population (N = 55) . | Phase 2 (n = 30) . | |||
| All grades . | Grade 3-4 . | All grades . | Grade 3-4 . | |
| Nausea | 21 (38.2) | 2 (3.6) | 11 (36.7) | 2 (6.7) |
| Platelet count decreased | 20 (36.4) | 11 (20.0) | 7 (23.3) | 3 (10.0) |
| Neutrophil count decreased | 19 (34.5) | 16 (29.1) | 9 (30.0) | 7 (23.3) |
| Anemia | 17 (30.9) | 11 (20.0) | 8 (26.7) | 7 (23.3) |
| Constipation | 17 (30.9) | 1 (1.8) | 8 (26.7) | 1 (3.3) |
| Serum creatinine increased | 14 (25.5) | 0 | 2 (6.7) | 0 |
| Diarrhea | 14 (25.5) | 1 (1.8) | 6 (20.0) | 1 (3.3) |
| Fatigue | 14 (25.5) | 1 (1.8) | 8 (26.7) | 0 |
| Decreased appetite | 12 (21.8) | 0 | 6 (20.0) | 0 |
| Vomiting | 11 (20.0) | 1 (1.8) | 5 (16.7) | 1 (3.3) |
| TEAE, n (%) . | Primary analysis . | |||
|---|---|---|---|---|
| Overall population (N = 55) . | Phase 2 (n = 30) . | |||
| All grades . | Grade 3-4 . | All grades . | Grade 3-4 . | |
| Nausea | 21 (38.2) | 2 (3.6) | 11 (36.7) | 2 (6.7) |
| Platelet count decreased | 20 (36.4) | 11 (20.0) | 7 (23.3) | 3 (10.0) |
| Neutrophil count decreased | 19 (34.5) | 16 (29.1) | 9 (30.0) | 7 (23.3) |
| Anemia | 17 (30.9) | 11 (20.0) | 8 (26.7) | 7 (23.3) |
| Constipation | 17 (30.9) | 1 (1.8) | 8 (26.7) | 1 (3.3) |
| Serum creatinine increased | 14 (25.5) | 0 | 2 (6.7) | 0 |
| Diarrhea | 14 (25.5) | 1 (1.8) | 6 (20.0) | 1 (3.3) |
| Fatigue | 14 (25.5) | 1 (1.8) | 8 (26.7) | 0 |
| Decreased appetite | 12 (21.8) | 0 | 6 (20.0) | 0 |
| Vomiting | 11 (20.0) | 1 (1.8) | 5 (16.7) | 1 (3.3) |
TEAE, treatment-emergent adverse event.